RN6G, a monoclonal antibody against Beta amyloid for the treatment of Geographic Atrophy in Age-Related Macular Degeneration[8]
RN909, a monoclonal antibody antagonist of the glucagon receptor for type 2 diabetes (T2DM)[9]
REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer[10]
PF-04518600, a monoclonal antibody targeting OX40 to enhance T cell functions and inhibit tumor growth[11]
Rinat was founded in 2001 by
Arnon Rosenthal,[12][13] who was also Rinat's president, chief scientific office and board director, and Patrick Lynn,[14] following a broad licensing agreement with
Genentech,[15] and was acquired by
Pfizer in 2006 for approximately $500M.[16][17] Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco.[18]